Fiscal Wizard · Single-issue tearsheet

MRK / May 11, 2026 Run #61

MRK

Merck & Co., Inc.

Drug Manufacturers - General

Composite verdict

B 64.9 / 100

Above-average across fundamentals and technicals.

Industry rank 1st of 3 in Drug Manufacturers - General

Phase D-Q rebuild: industry-lens routing + ATR-relative MA rejection + Damodaran-15 + canonical preset switches

Fundamentals Above average

64.9 / 100

How the books look — profitability, leverage, valuation, growth. · 46 metrics weighted.

Strongest
Weakest
EBITDA Margin 100
Cash Conversion Cycle 0
Cash Ratio 99
Inventory Turnover 0
Interest Coverage 98
Revenue Growth (YoY) 5

Technicals Above average

64.8 / 100

How the chart looks — momentum, trend, volume, volatility. · 31 signals weighted.

Strongest
Weakest
Fibonacci Retracement 100
Donchian Breakout 0
Regime Filter 100
Relative Strength vs SPY 3
Bollinger Mean Reversion 100
MACD Signal Cross 11

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MRK.